Table 5.
Adverse events of gemcitabine plus nab-paclitaxel.
| Adverse Events | n = 103 | ||
|---|---|---|---|
| All Grades | Grade ≥ 3 | ||
| Hematologic adverse events, n (%) | |||
| Anemia | 102 (99.0) | 30 (29.1) | |
| Neutropenia | 80 (77.7) | 48 (46.6) | |
| Thrombocytopenia | 93 (90.3) | 38 (36.9) | |
| Non-hematologic adverse events, n (%) | |||
| Febrile neutropenia | 1 (1.0) | 1 (1.0) | |
| Nausea/vomiting | 53 (51.5) | 0 (0) | |
| Anorexia | 15 (14.6) | 0 (0) | |
| Diarrhea | 41 (39.8) | 0 (0) | |
| Constipation | 65 (63.1) | 0 (0) | |
| Stomatitis | 21 (20.4) | 0 (0) | |
| Alopecia | 91 (88.3) | 0 (0) | |
| Eruption | 23 (22.3) | 0 (0) | |
| Skin hyperpigmentation | 7 (6.8) | 0 (0) | |
| Fatigue | 93 (90.3) | 2 (1.9) | |
| Peripheral neuropathy | 89 (86.4) | 1 (1.0) | |
| Hypertension | 3 (2.9) | 0 (0) | |
| AST/ALT increased | 91 (88.3) | 6 (5.8) | |
| Creatinine increased | 16 (15.5) | 0 (0) | |
| Interstitial pneumonia | 2 (1.9) | 2 (1.9) | |
AST, aspartate aminotransferase; ALT, alanine aminotransferase.